Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 16 Nov 2005 |
| Abbott reports improved clinical course with Orion?s levosimendan (Simdax®) when added to standard t | 14 Nov 2005 |
| Orion Corporation share capital increase entered in the Trade Register | 11 Nov 2005 |
| Orion Group Interim Report 1-9/2005 | 8 Nov 2005 |
| Matters to be handled at Orion?s Extraordinary General Meeting of Shareholders on 19 December 2005 | 8 Nov 2005 |